Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Silver Range Resources: A hidden gem in the mining industry (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Oncolytics Biotech Inc ONCY


Primary Symbol: T.ONC

Healthcare Biotechnology
Oncolytics Biotech Inc. is a biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to phase 3 licensure-enabling studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.


TSX:ONC - Post by User

Oncolytics Biotech Inc > oh dear
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(87)
•••
Comment by Quentin30on Jun 05, 2023 10:25am
99 Views
Post# 35480279

RE:RE:RE:RE:oh dear

RE:RE:RE:RE:oh dearAzzak34 - KOL presentation... and compelling new data...  yet ONCY pps is down again. 

Please explain what I am missing...? What is it the market seems to dislike about this company ? Is it perhaps 24 years of missed timelines, non statisically powered data, unclear signals of efficacy, prior failed Phase III trial, ?

Clinical Trial partners who have exclusive access to the data and walk away... 

does none of this concern you..? or are you perfectly happy with how this company is being run, the decisions made, and then results thus far presented..?

well, I suppose we only have until 2028 to get this approved, before any old tom can make it... maybe you azzak, maybe even you..
<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities